📰 Nuclear Export News
Page 4 - Nuclear Export News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nuclear Export. Real-time updates on events, politics, business and more.
October 11, 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received a consensus rating of “Moderate Buy” from the five research firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective […]
October 2, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
September 28, 2023
Kennedy Investment Group raised its holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Free Report) by 75.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 35,000 shares of the company’s stock after buying an additional 15,000 shares during the quarter. Kennedy Investment Group’s holdings in […]
September 26, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
September 16, 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been given an average recommendation of “Moderate Buy” by the five ratings firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among […]
September 16, 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month target […]
September 15, 2023
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) Director Garen G. Bohlin acquired 41,140 shares of Karyopharm Therapeutics stock in a transaction dated Tuesday, September 12th. The stock was bought at an average price of $1.22 per share, with a total value of $50,190.80. Following the completion of the purchase, the director now directly owns […]
September 13, 2023
Presenter SpeechMichael Ulz All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. Im Michael Ulz, one of the biotech analysts here, and...
September 5, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
September 1, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the...